Skip to main content
Premium Trial:

Request an Annual Quote

Not Worth It Anymore

Fewer investors are putting money into new drug and device-makers because of regulatory concerns, reports Bloomberg. A survey conducted by the National Venture Capital Association found that about 40 percent of the 150 venture capital firms that responded decreased their life science investment in the last three years. "The process has gotten to be so long, and the capital required so deep, that it’s becoming more and more difficult to generate venture-type returns and therefore make it worth your while to do it," says Polaris Venture Partners' Terry McGuire.

A separate Bloomberg article says that biotech stocks are now tending to fall even after firms receive approval for their drugs. "[Investors] fear the risks of commercial disappointment," says Michael Yee from RBC Capital Markets. "That's a reflection of underappreciated commercial logistical issues with the launch, as well reimbursement hurdles at the start, and physician comfort in the first few months."

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.